Brief: Caplin Point Laboratories gets U.S. FDA approval for ketorolac tromethamine injection
20/09/2017 05:54
Sept 20 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS
* Says gets FDA approval for ketorolac tromethamine
injection 30 mg/ml in U.S.
* Says ketorolac tromethamine injection will be manufactured
at Caplin's FDA approved site
Source text - http://bit.ly/2yoo3PA
Further company coverage: CAPL.NS
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Caplin Point Laboratories
See all newsBrief: Caplin Point Laboratories Says US FDA Completes Unannounced Inspection Of Caplin Steriles Gummidipoondi Facility
Brief: Caplin Point Laboratories March-Quarter Consol Net Profit 1.7 Bln Rupees
Brief: Caplin Point Laboratories Unit Receives Final USFDA Approval For ANDA Potassium Phosphates Injection
Brief: Caplin Point Laboratories Says Unit Receives USFDA Approval For Sodium Phosphates Injection
Brief: Caplin Point Laboratories Dec-Quarter Consol Net Profit 1.64 Billion Rupees